Tessera Therapeutics was founded in 2018 by Jake Rubens and Geoffrey von Maltzahn. The company has not publicly endorsed plans to participate in an IPO.

Tessera is a biotech company developing gene editing technology to fight disease. The company has raised more than $500 million in venture capital funding from investors including SoftBank Vision Fund 2, T. Rowe Price Associates, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, and the Abu Dhabi Investment Authority. The company did not disclose valuation figures following a $300 million Series C fundraising round in 2022.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Tessera, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Tessera's ticker symbol?

Tessera does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Tessera's stock price?

The stock price for Tessera will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Tessera's major investors?

ARTIS Ventures
Toba Capital
Flagship Pioneering
March Capital
TA Ventures
Longevity Vision Fund

Tessera Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
4/19/2022 Series C $300MM raised $XXX.XX $XXX.XX
1/12/2021 Series B $232.5MM raised $XXX.XX $XXX.XX
7/7/2020 Series A, A-1 and A-2 $26.41MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Tessera

Forge green plus iconForge green minus icon

What is Tessera funding to date?

Tessera has raised $558.91MM to date.
Forge green plus iconForge green minus icon

When was Tessera founded?

Tessera was founded in 2018.
Forge green plus iconForge green minus icon

Can you invest in Tessera?

Tessera is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Tessera share pre-IPO?

If you own Tessera pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Tessera a publicly traded company?

Tessera is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.